Bruton tyrosine kinase inhibition: Clinical relevance beyond B cells

Affiliations

¹ Women's Guild Lung Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, Calif.
² Women's Guild Lung Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, Calif. Electronic address: suzanne.cassel@cshs.org.

Editorial

Balaji Banoth et al. J Allergy Clin Immunol. 2017 Oct.

. 2017 Oct;140(4):985-987.

doi: 10.1016/j.jaci.2017.03.041. Epub 2017 Apr 26.

¹ Women's Guild Lung Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, Calif.
² Women's Guild Lung Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, Calif. Electronic address: suzanne.cassel@cshs.org.

No abstract available

Keywords: Bruton tyrosine kinase; Nucleotide-binding leucine-rich repeat receptor family pyrin domain containing protein 3; ibrutinib.

Comment on

Human NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase.
Liu X, Pichulik T, Wolz OO, Dang TM, Stutz A, Dillen C, Delmiro Garcia M, Kraus H, Dickhöfer S, Daiber E, Münzenmayer L, Wahl S, Rieber N, Kümmerle-Deschner J, Yazdi A, Franz-Wachtel M, Macek B, Radsak M, Vogel S, Schulte B, Walz JS, Hartl D, Latz E, Stilgenbauer S, Grimbacher B, Miller L, Brunner C, Wolz C, Weber ANR. Liu X, et al. J Allergy Clin Immunol. 2017 Oct;140(4):1054-1067.e10. doi: 10.1016/j.jaci.2017.01.017. Epub 2017 Feb 16. J Allergy Clin Immunol. 2017. PMID: 28216434